Takashi Seto

27.3k total citations · 4 hit papers
365 papers, 8.7k citations indexed

About

Takashi Seto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Takashi Seto has authored 365 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 311 papers in Pulmonary and Respiratory Medicine, 263 papers in Oncology and 60 papers in Molecular Biology. Recurrent topics in Takashi Seto's work include Lung Cancer Treatments and Mutations (280 papers), Lung Cancer Research Studies (142 papers) and Lung Cancer Diagnosis and Treatment (107 papers). Takashi Seto is often cited by papers focused on Lung Cancer Treatments and Mutations (280 papers), Lung Cancer Research Studies (142 papers) and Lung Cancer Diagnosis and Treatment (107 papers). Takashi Seto collaborates with scholars based in Japan, United States and Germany. Takashi Seto's co-authors include Nobuyuki Yamamoto, Kazuhiko Nakagawa, Makoto Nishio, Isamu Okamoto, Toyoaki Hida, Masahiro Fukuoka, Kōichi Goto, Gouji Toyokawa, Takeharu Yamanaka and Yukito Ichinose and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Takashi Seto

342 papers receiving 8.6k citations

Hit Papers

Erlotinib alone or with bevacizumab as first-line therapy... 2013 2026 2017 2021 2014 2013 2017 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
    2014 561 citations Takashi Seto, Terufumi Kato et al. The Lancet Oncology profile →
  2. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
    2013 449 citations Takashi Seto, Makoto Nishio et al. The Lancet Oncology profile →
  3. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
    2017 308 citations Toshiaki Takahashi, Takeharu Yamanaka et al. The Lancet Oncology profile →
  4. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
    2018 225 citations Takashi Seto, Noboru Yamamoto et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takashi Seto Japan 47 6.6k 6.1k 2.2k 1.2k 887 365 8.7k
Philip Bonomi United States 42 4.4k 0.7× 4.9k 0.8× 2.1k 0.9× 978 0.8× 652 0.7× 241 8.0k
Haruyasu Murakami Japan 40 3.7k 0.6× 3.8k 0.6× 1.4k 0.6× 908 0.8× 689 0.8× 306 6.1k
Maya Gottfried Israel 33 7.7k 1.2× 10.7k 1.8× 1.9k 0.9× 1.7k 1.5× 940 1.1× 156 13.3k
M. Catherine Pietanza United States 44 3.9k 0.6× 6.0k 1.0× 1.6k 0.7× 724 0.6× 1.9k 2.1× 121 7.5k
Tibor Csőszi United States 22 5.8k 0.9× 9.1k 1.5× 1.3k 0.6× 1.3k 1.1× 746 0.8× 82 10.7k
Rafał Dziadziuszko Poland 44 6.3k 1.0× 5.8k 1.0× 2.7k 1.2× 1.8k 1.6× 413 0.5× 290 9.0k
Hiroshi Nokihara Japan 40 3.3k 0.5× 3.9k 0.6× 1.7k 0.7× 935 0.8× 656 0.7× 237 5.9k
Katsuyuki Hotta Japan 40 8.7k 1.3× 11.2k 1.8× 2.1k 0.9× 1.7k 1.5× 781 0.9× 288 14.1k
Rogério Lilenbaum United States 33 5.5k 0.8× 5.6k 0.9× 2.1k 1.0× 1.2k 1.0× 334 0.4× 105 8.4k
Sinéad Cuffe Ireland 27 5.8k 0.9× 8.6k 1.4× 1.8k 0.8× 1.7k 1.4× 425 0.5× 102 11.1k

Countries citing papers authored by Takashi Seto

Since Specialization
Citations

This map shows the geographic impact of Takashi Seto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takashi Seto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takashi Seto more than expected).

Fields of papers citing papers by Takashi Seto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takashi Seto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takashi Seto. The network helps show where Takashi Seto may publish in the future.

Co-authorship network of co-authors of Takashi Seto

This figure shows the co-authorship network connecting the top 25 collaborators of Takashi Seto. A scholar is included among the top collaborators of Takashi Seto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takashi Seto. Takashi Seto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Umemura, Shigeki, Chih‐Hsi S. Kuo, Virote Sriuranpong, et al.. (2024). Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).. Journal of Clinical Oncology. 42(16_suppl). 8637–8637.
3.
4.
Nosaki, Kaname, Kiyotaka Yoh, Hidehito Horinouchi, et al.. (2024). Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study. International Journal of Clinical Oncology. 29(8). 1142–1151.
5.
Yoshida, Tatsuya, Toru Kumagai, Ryo Toyozawa, et al.. (2023). Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial. Cancer Science. 114(9). 3698–3707. 7 indexed citations
6.
Kenmotsu, Hirotsugu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.. (2023). Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(34). 5242–5246. 8 indexed citations
7.
Sugawara, Shunichi, Masashi Kondo, Toshihide Yokoyama, et al.. (2022). Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. International Journal of Clinical Oncology. 27(12). 1828–1838. 5 indexed citations
8.
Nakagawa, Kazuhiko, Ernest Nadal, Edward B. Garon, et al.. (2021). RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(19). 5258–5271. 29 indexed citations
9.
Matsubara, Taichi, Shinkichi Takamori, Takatoshi Fujishita, et al.. (2021). Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy. Thoracic Cancer. 12(23). 3286–3289. 1 indexed citations
10.
Yoh, Kiyotaka, Takashi Seto, Miyako Satouchi, et al.. (2021). Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. Lung Cancer. 155. 40–45. 17 indexed citations
11.
Ono, Akira, Haruyasu Murakami, Takashi Seto, et al.. (2020). Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. Drugs in R&D. 21(1). 65–78. 4 indexed citations
12.
Nishio, Makoto, Tatsuya Yoshida, Toru Kumagai, et al.. (2020). Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. Journal of Thoracic Oncology. 16(3). 452–463. 47 indexed citations
13.
Takeda, Masayuki, Yuichiro Ohe, Hidehito Horinouchi, et al.. (2019). Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung Cancer. 137. 64–70. 10 indexed citations
14.
Katsuya, Yuki, Hidehito Horinouchi, Takashi Seto, et al.. (2019). Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. European Journal of Cancer. 113. 78–86. 104 indexed citations
15.
Kometani, Takuro, Kenji Sugio, Atsushi Osoegawa, Takashi Seto, & Yukito Ichinose. (2018). Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene. Thoracic Cancer. 9(5). 563–570. 8 indexed citations
16.
Kogure, Yoshihito, Hideo Saka, Yuichi Takiguchi, et al.. (2018). A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer. 19(5). e711–e715. 8 indexed citations
17.
Hida, Toyoaki, Takashi Seto, Hidehito Horinouchi, et al.. (2018). Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9. Cancer Science. 109(9). 2863–2872. 43 indexed citations
18.
Seto, Takashi, Terufumi Kato, Makoto Nishio, et al.. (2014). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. The Lancet Oncology. 15(11). 1236–1244. 561 indexed citations breakdown →
19.
Seto, Takashi, et al.. (1999). A Case of Multiple Lung Metastases from Angiosarcoma of the Uterus.. Haigan. 39(4). 453–457. 1 indexed citations
20.
Seto, Takashi. (1979). Chemotherapy for lung cancer.. BMJ. 2(6194). 815–816. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Haruyasu Murakami Breakdown of academic impact, for papers by Maya Gottfried Breakdown of academic impact, for papers by M. Catherine Pietanza Breakdown of academic impact, for papers by Tibor Csőszi Breakdown of academic impact, for papers by Rafał Dziadziuszko Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Katsuyuki Hotta Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by Sinéad Cuffe
Rankless by CCL
2026